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Abstract
Malaria parasites harbour two organelles with bacteria-like metabolic processes that are the targets of many anti-bacterial
drugs. One such drug is fusidic acid, which inhibits the translation component elongation factor G. The response of P.
falciparum to fusidic acid was characterised using extended SYBR-Green based drug trials. This revealed that fusidic acid kills
in vitro cultured P. falciparum parasites by immediately blocking parasite development. Two bacterial-type protein
translation elongation factor G genes are identified as likely targets of fusidic acid. Sequence analysis suggests that these
proteins function in the mitochondria and apicoplast and both should be sensitive to fusidic acid. Microscopic examination
of protein-reporter fusions confirm the prediction that one elongation factor G is a component of parasite mitochondria
whereas the second is a component of the relict plastid or apicoplast. The presence of two putative targets for a single
inhibitory compound emphasizes the potential of elongation factor G as a drug target in malaria.
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Introduction
Numerous anti-bacterials are also effective anti-malarials and
are a part of current malaria management programs. For instance,
doxycycline is widely prescribed for malaria chemoprophylaxis [1]
and clindamycin and doxycycline are recommended for use in
ACT therapy in the case of initial treatment failure [2]. Anti-
bacterials typically work by blocking vital prokaryotic processes
such as DNA replication, RNA transcription, protein translation,
or peptidoglycan wall synthesis. The key to the success of anti-
bacterials is that they specifically target the fundamental
differences between these processes in bacteria and the equivalent
processes in humans and other eukaryotes. How anti-bacterials kill
eukaryotic malaria parasites is not well understood. Two malaria
parasite organelles derived from endosymbiotic bacteria, the
mitochondrion and the relict plastid (or apicoplast), are the likely
targets of these compounds.
Mitochondria occur in most eukaryotes and derive from an
alpha proteobacterium that entered into an endosymbiotic
partnership with a host cell at the outset of eukaryotic evolution
[3]. Though much reduced, mitochondria retain clear hallmarks
of their bacterial ancestry, and their housekeeping and metabolic
activities are essentially bacterial in nature. Plastids are typically
the site of photosynthesis in algae and plants and derive ultimately
from endosymbiotic cyanobacteria. A vestigial plastid that lacks
the ability to photosynthesize was identified more than a decade
ago in malaria parasites [4] and is indispensable for parasite
survival [5]. It is now clear that non-photosynthetic plastids occur
in almost all members of the Phylum Apicomplexa, where they are
referred to as apicoplasts. Recently, a photosynthetic apicoplast
was discovered in an apicomplexan symbiont of corals [6],
confirming the hypothesis that the ancestors of apicomplexan
parasites were photosynthetic autotrophs and converted to
parasitism of animals early on in their evolutionary radiation.
Apicoplasts are reminiscent of mitochondria in that they retain
numerous hallmarks of their bacterial ancestry but their metabolic
suite is markedly different, being derived from a different lineage
of bacterial ancestors-the photosynthetic cyanobacteria.
Fusidic acid is a potent, narrow spectrum steroid anti-bacterial
derived from the fungus Fusidium coccineum [7]. It is often used in
conjunction with rifampicin to treat severe Gram-positive bacterial
infections, such as methicillin-resistant Staphylococcus aureus
(MRSA). Fusidic acid targets elongation factor G (EF-G), a
GTPase critical to the translocation step of bacterial protein
synthesis [8]. Fusidic acid binds to EF-G on the ribosome and
prevents the EF-G:GDP complex from leaving the ribosome,
effectively stalling protein synthesis by steric inhibition [9]. Fusidic
acid exhibits anti-Plasmodium activity in vitro [10], but it has never
been utilized as an anti-malarial and nothing is known about its
mode of action.
Both the apicoplast and the mitochondrion apparently maintain
bacterial-style translation machineries that are candidate targets
for fusidic acid. Hard evidence for translation has only been
obtained for the Plasmodium falciparum apicoplast courtesy of an
antibody directed against elongation factor Tu that is encoded on
the apicoplast genome [11]. No such evidence for translation in
malaria parasite mitochondria exists, but assays of their predicted
enzymatic activity suggest that the three proteins encoded by the
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the mitochondria [12]. This evidence is supported by the presence
of ribosomal RNAs [13] and a host of nucleus-encoded bacterial-
like translation components that are targeted to the mitochondrion
[14].
With a view to further defining the likely target of fusidic acid in
malaria parasites, we explore whether either or both of these
organellar translation systems utilize EF-G. Drug trials confirmed
the anti-parasitic activity of fusidic acid but demonstrate different
characteristics to other bacterial translation inhibitors. Searches of
the P. falciparum genome for EF-G encoding genes identified two
candidates. Bioinformatic analysis and protein sequence compar-
isons of the predicted protein sequence indicate that one candidate
gene is of mitochondrial origin and the other is of a plastid origin.
The two gene products localize to the predicted organelles, further
confirming that protein translation is occurring in both the
apicoplast and mitochondria and suggesting that one or both of
these proteins is the target of fusidic acid.
Results
Fusidic acid kills P. falciparum in the first cycle
Most drugs targeting translation in the apicoplast produce a
delayed effect in which the treated parasites grow and replicate
normally for one life cycle following drug treatment, then die after
invading a new blood cell [15,16,17]. To test for this drug response
we determined the IC50 for fusidic acid in in vitro cultures of the P.
falciparum line D10. The IC50 values after one life cycle
(,48 hours) are similar to those previously reported [10] and
only slightly higher than the values found after two cycles
(,96 hours) (Fig. 1A) indicating that fusidic acid’s effects are
immediate. This contrasts with other translation-blocking anti-
bacterials, such as azithromycin, clindamycin and tetracycline,
which exhibit delayed death and have dramatically lower IC50
values at 96 hours compared to 48 hours (Fig. 1A, [15,17]).
Examination of parasite lines exposed to fusidic acid at
concentrations equivalent to the 96 hour IC90 confirmed the
immediate effect. Parasites treated with fusidic acid in early ring
stages failed to progress beyond the early trophozoite stage.
Consistent with this growth arrest is the lack of significant genome
replication and a failure of the organelles to elongate (Fig. 1B).
This contrasts with exposure to ‘‘delayed-death’’ antibiotics, where
treatments with drug concentrations well in excess of the IC90
show no effect on parasite or organellar development during the
first 48 hours of drug treatment [15,17]. It was interesting to note
that many of the fusidic acid treated parasites remained within the
red blood cell after 48 hours of treatment but were no longer
detectable by confocal microscopic examination after a further
48 hours and no nuclear division or merozoite formation was
observed during this period. The progressive loss of drug-killed
parasites may account for the slight reduction in IC50 values
between 48 and 96 hours, as the assay used does not differentiate
between live parasites and those dead and dying parasites
remaining within the red blood cell.
P. falciparum encodes two EF-G proteins of bacterial
ancestry
Searches of the P. falciparum genome identified two candidate
EF-G encoding genes (PFL1590c and PFF0115c) both of which
contain GTPase domains. PFL1590c encodes a protein of 803
amino acids that, excluding apicomplexan orthologues, is most
similar to the EF-G encoding (fusA) gene of the delta proteobacter-
ium Myxococcus xanthus (Genbank accession NC_008095.1) with
which it shares 42 % amino acid identity. PFF0115c encodes a
protein of 937 amino acids that, excluding apicomplexan
orthologues, is most similar to the EF-G encoding (fusA) gene of
the actinobacterium Nocardioides sp. (Genbank accession
NC_008699.1), with which it shares 46 % amino acid identity.
The presence of two bacterium-like EF-G proteins in P. falciparum
is suggestive of an organellar localisation for these proteins and is
consistent with the parasites sensitivity to fusidic acid.
Alignments of putative P. falciparum nucleus-encoded
EF-G proteins reveals that the two proteins are distinct
We aligned the two P. falciparum EF-G protein sequences with
characterised and predicted EF-G sequences from other apicom-
plexans, algae, higher plants, insects and mammals. We also
included the sequence of the previously crystallised Thermus
thermophilus EF-G [18] as a reference for structural features.
Accession numbers for protein sequences used in the alignment
are listed in Table S1.
The alignment of the GTPase domains of these proteins defines
two distinct groups, with a number of amino acids conserved
within each group but differing between the two (Fig. 2Ai, blue
and green boxes). The smaller of the putative P. falciparum EF-Gs
(PFL1590c) and other predicted mitochondrial EF-Gs clearly
group with eukaryotes that do not contain a plastid (i.e. human
and Anopheles mosquito) and with the EF-G localised to the
mitochondria in higher plants [19,20]. The larger of the two PfEF-
Gs (PFF0115c) groups with the plastid-localised EF-G from higher
plants [21,22] and the predicted plastid EF-Gs from other
organisms (Fig. 2Ai). The grouping of the mitochondrial and
plastid EF-Gs is also evident in alignments of other portions of the
protein (Fig. 2A ii, iii), although the overall amino acid
conservation in these regions is much lower making the
associations less obvious. Indeed, in several instances, specific
amino acids are conserved in all EF-Gs except the Plasmodium
proteins. The grouping of EF-Gs in our alignment correlates with
a recently published phylogenetic analysis of bacterial and
organellar EF-Gs, which concluded that the phylogenetic signal
for the apicomplexan EF-Gs is too weak to draw detailed
conclusions about their relationships to other EF-Gs beyond the
organellar origin. [23]
To gain insight into the possible targets of fusidic acid in P.
falciparum, we compared the conservation of amino acids known to
confer fusidic acid resistance in various bacteria. These amino
acids occur in three areas of the protein corresponding to
Figure 2A i, ii and iii [24]. Amino acid residues identified as
interacting with fusidic acid in crystallographic studies [25] are
largely conserved in all EF-Gs examined, particularly in the
GTPase domain (Fig. 2A i, ii black arrows). While several of the
fusidic acid interacting amino acids in P. falciparum differ from the
bacterial residues in the second region, none of the changes
correspond to those conferring resistance. They do suggest
differences between plastid-localised and mitochondrial EF-Gs
(T437-starred) and unique amino acids in the Plasmodium EF-Gs
(H458, R465-starred).
Other residues that have been correlated with resistance or
hypersensitivity but do not interact directly with fusidic acid are
highlighted with red and blue arrows, respectively. There is less
conservation among these residues than those directly interacting
with fusidic acid, but the pattern of conservation in these amino
acids is similar to the fusidic acid interacting residues. There are
several differences highlighting the separation of mitochondrial
and plastid EF-Gs (D109 and E119, starred) and of the Plasmodium
EF-Gs and all others (P436, M450, G617 – starred). Only one
difference suggests enhanced resistance; the amino acid methio-
nine 453 (black pound sign) is altered in the putative P. falciparum
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(4-fold) resistance in Staphylococcus aureus [26].
Bioinformatic analyses suggest that PFL1590c is a
mitochondrial-targeted protein and that PFF0115c is an
apicoplast-targeted protein
Nucleus encoded organelle-targeted proteins typically contain
an N-terminal targeting peptide that directs them either to the P.
falciparum mitochondrion [27] or apicoplast [28]. Alignment of the
two putative EF-G proteins encoded by the P. falciparum genes
PFL1590c and PFF0155c with EF-G from the bacterium T.
thermophilus indicated that both malaria parasite proteins bear N-
terminal extensions (Fig. 2B). The 44 amino acid N-terminal
extension (Fig. 2B green box) of the PFL1590c protein was
designated by the Plasmodium mitochondrial-targeting prediction
program PlasMit [27] to be a likely mitochondrial targeting
peptide (Table S2). The 103 amino acid N-terminal extension of
PFF0115c (Fig. 2B blue box) is predicted to contain both a signal
peptide and a transit peptide by the Plasmodium apicoplast targeting
prediction program PlasmoAP [29], so PFF0115c is likely an
apicoplast-targeted protein (Table S2).
PFL1590c is a nucleus-encoded mitochondrial-targeted
EF-G protein involved in P. falciparum mitochondrial
translation
To provide insight into the localisation of PFL1590c, we
transfected D10 parasite lines with constructs containing this
putative EF-G fused to a 3x hemagglutinin (HA) tag at the C-
terminus and driven by the 59 region of PfHSP86, which we call
MitoEFG-HA (Fig. 3A). Western blot analysis of the transgenic
parasites confirmed expression of the recombinant protein. A
single band of ,96 kDa was detected, which matches the size of
Figure 1. Fusidic acid kills malaria parasites within the first life cycle. A. Parasiticidal activity of fusidic acid on in vitro cultured erythrocyte
stages of Plasmodium falciparum. Fusidic acid kills parasites with an IC50 of 52.8 mM (S.E. 2.5, n=3) after 48 hours (one life cycle). After drug treatment
over two erythrocytic cycles, the IC50 of fusidic acid (36.6 mM S.E. 2.4, n=3) is not significantly lower as compared the difference seen for azithromycin
(14.4 mM( +/20.85) v. 0.0750 mM( +/2.015), n=3); death of malaria parasites is immediate and not delayed. B. Synchronised ring-stage parasites
expressing RFP targeted to the apicoplast (red) and YFP targeted to the mitochondria (green) were exposed to i) 80 mM of fusidic acid (IC90) or left
untreated ii) for 40 hours, the nuclei were stained with Hoescht 33342 (blue) and viewed by confocal laser microscopy.
doi:10.1371/journal.pone.0020633.g001
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tag (Fig. 3B). Transit peptides are usually removed after trafficking
to the mitochondria and the slight mass anomaly may be due to
small differences in predicted and observed molecular mass that
are not unusual in polyacrylamide gel electrophoresis.
Immunofluorescence analysis of parasites expressing this
episome revealed that the MitoEFG-HA fusion protein is localised
to the P. falciparum mitochondrion (Fig. 3C). MitoTracker labelling
of the mitochondrion co-localised with staining of the MitoEFG-
HA protein. Both MitoTracker labelling and antibody staining of
the MitoEFG-HA protein reveal a large, crescent shaped organelle
characteristic of the P. falciparum mitochondrion during the late
trophozoite stage of the parasite’s asexual cycle [22].
To confirm that the organelle containing PFL1590c is the
mitochondrion, we compared the localisation of the MitoEFG-HA
fusion protein with the apicoplast resident acyl carrier protein
(ACP) [28]. The signal from the HA tagged protein clearly
localises to an intercellular compartment distinct from the
apicoplast (Fig. 3D), further confirming that PFL1590c is a
nucleus-encoded EF-G protein targeted exclusively to the P.
falciparum mitochondrion.
PFF0115c is a nucleus-encoded apicoplast-targeted EF-G
protein involved in P. falciparum apicoplast translation
Bioinformatic analysis revealed that PFF0115c has all the
characteristics of a nucleus-encoded apicoplast-targeted protein.
To localise PFF0115c, we transfected constructs containing this
putative EF-G fused to a C-terminal GFP in a construct driven by
the 59 region of PfHSP86, which we called ApicEFG-GFP
(Fig. 4A). Western blot analysis of parasites expressing ApicEFG-
GFP showed a band of between 120 and 160 kDa in mass. This
corresponds reasonably well with the predicted molecular mass of
Figure 2. Bioinformatic analysis of P. falciparum EF-Gs. A. Sequence alignment of Plasmodium falciparum EF-G proteins, selected eukaryotic EF-
Gs and the previously crystallised EF-G from the bacterium Thermus thermophilus. Only the three regions known to carry fusidic acid resistance
mutations are shown. Red boxes indicate amino acids conserved across all EF-Gs. Blue and dark green boxes highlight amino acids conserved within
the mitochondrial or plastid EF-Gs, respectively. Light green, orange and pink boxes indicate amino acids conserved in all but the Plasmodium EF-Gs,
Plasmodium mitochondrial EF-Gs and Plasmodium apicoplast EF-Gs, respectively. Arrows indicate amino acids known to be involved in fusidic acid
activity. Black arrows indicate amino acids that directly interact with fusidic acid. Red and blue arrows indicate amino acids that do not interact
directly with fusidic acid but whose mutation can cause resistance and hypersensitivity, respectively. Stars indicate residues that differ between
mitochondrial and plastid EF-Gs. The pound sign indicates the only residue in P. falciparum mitochondrial EF-G in which the wild type amino acid may
confer resistance to fusidic acid. Assignment of EF-Gs to cellular location is based on published studies for A.thaliana [20,22], H. sapiens [41] and O.
sativa [21,23] and bioinformatic analysis of targeting sequences for the other proteins. B. Sequence alignment of the N-terminal region of the EF-Gs
from P. falciparum and T. thermophilus. Red boxes indicate areas of homology between the three proteins. Blue and green boxes highlight the N-
terminal extensions of the two P. falciparum proteins used to predict protein targeting.
doi:10.1371/journal.pone.0020633.g002
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highly expressed apicoplast-targeted proteins show a second,
larger product that corresponds to a preprocessed form of the
protein that retains the apicoplast transit peptide while transiting
to the apicoplast [30]. No such product was noted on the Western
Blot (Fig. 4B). This is not unusual and likely results from the low
levels of recombinant protein expression in this experiment.
Immunofluorescence assays on parasites expressing the Api-
cEFG-GFP episome in conjunction with ACP as an apicoplast
marker [28] reveal that PFF0115c is indeed localised to the P.
falciparum apicoplast (Fig. 4C). Both ACP antibody labelling and
ApicEFG-GFP fluorescence revealed a dot-like organelle in the
parasite, characteristic of the apicoplast in ring stage parasites
during the asexual cycle [31]. These data confirm that the gene
annotated as PFF0115c is a nucleus-encoded EF-G protein
targeted to the P. falciparum apicoplast.
Discussion
We have shown that fusidic acid, an anti-bacterial that stalls
bacterial protein translation by binding to EF-G, kills malaria
parasites with an IC50 of 52.8 mM. This inhibitory concentration
falls within the range seen for other bacterial translation inhibitors
when applied for only a single plasmodium life cycle [15,17],
although it is much higher than that seen after prolonged exposure
of those compounds causing the delayed-death effect [15,16,17]. It
is also too high for fusidic acid itself to be an effective drug.
However, fusidic acid has only an immediate effect, suggesting that
this compound kills Plasmodium via a different mechanism that the
delayed-death anti-bacterials and may present an effective lead
compound for drug development. The inhibitory concentration of
any compound reflects many factors, including differences in their
ability to come in contact with the target molecule, affinity for the
site of action and the ability of the inhibitor to block target activity.
All of these factors may be contributing to the IC50 of fusidic acid
against P. falciparum and need to be optimised during further drug
development. Determining the specific target of fusidic acid is an
important first step in assessing these factors in a systematic way.
Two candidate EF-G proteins that may be fusidic acid targets
were identified and localised (Fig. 2–4). Bioinformatic analysis is
consistent with these proteins having been introduced as
endosymbiont-derived genes that are now located in the parasite
nucleus. One EF-G is localised in the parasite mitochondrion, and
the second is localised to the relict plastid or apicoplast (Fig. 3,4).
Comparisons between primary protein structure of the apicoplast
and mitochondrial EF-Gs and sensitive bacterial EF-G proteins
suggests that the apicoplast localised EF-G is sensitive to fusidic
acid while the mitochondrial EF-G carries a single amino acid
residue that confers a weak resistance phenotype in S. aureus
(Fig. 2,[26]). Although this finding implies that the P. falciparum
mitochondrial EF-G may be resistant to fusidic acid, differences
between the bacterial and Plasmodium mitochondrial EF-Gs at
other conserved positions makes it difficult to draw specific
conclusions about the sensitivity of the P. falciparum mitochondrial
EF-G to fusidic acid from this single amino acid change without
further investigation. A further possibility is that fusidic acid acts
by targeting a mechanism unrelated to organellar protein
synthesis, but the two EF-Gs identified here represent the most
likely targets and require further investigation.
The identification of two nucleus-encoded, organelle localised
EF-Gs that could be the target of the same inhibitor presents
unique opportunities for the investigation of the effects of organelle
specific drugs and in the development of novel anti-malarials. For
almost all anti-bacterial compounds currently in use, the target (or
predicted target) is encoded on the genome of at least one of the
organelles [15,17,32] making them refractory to genetic manip-
Figure 3. P. falciparum EF-G PFL1590c localises to the mitochondrion. A. PFL1590c was fused to a 3x-HA tag to create the construct MitoEFG-
HA. B. Western blot analysis of D10 parasites expressing MitoEFG-HA reveals a single band at ,96 kDa, approximately the mass of the PFL1590c
protein fused to a 3x-HA tag. C. An immunofluorescence assay on D10 parasites expressing MitoEFG-HA reveals that PFL1590c is localised to the P.
falciparum mitochondrion. MitoEFG-HA (green) co-localises with MitoTracker labelling of the mitochondrion (red). DNA stained with Hoescht 33342
(blue). D. An immunofluorescence assay on the MitoEFG-HA expressing parasites counterstained with the ACP antibody as an apicoplast marker [29].
MitoEFG-HA protein localises to the typically elongated mitochondrion (green), but does not co-localise with the punctate apicoplast (red). DNA
stained with Hoescht 33342 (blue).
doi:10.1371/journal.pone.0020633.g003
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encoded EF-Gs in both the mitochondrion and apicoplast provides
the opportunity to use known bacterial resistance mutations to
dissect the effects of specifically blocking protein synthesis in each
organelle. It also presents the possibility of developing novel
compounds that target EF-G in both organelles, thereby yielding a
single anti-malarial compound that could have all the advantages
of a multi-drug therapy in terms of avoiding drug resistance.
Materials and Methods
Fusidic acids drug trials
Drug trials on P. falciparum line D10, were performed as
previously described [17]. Parasitemia was assessed using a
modified version [17] of the SYBR-Green assay [33]. Inhibitory
concentrations were calculated using the Hill-Slop method
available in SigmaPlot (Systat software).
Bioinformatic analysis of EF-G in P. falciparum
Protein sequences of the putative mitochondrial EF-G,
PFL1590c, and the putative apicoplast EF-G, PFF0115c, were
obtained from the Plasmodium Genome Resource (www.plasmodb.
org) as were sequences for putative homologs from Plasmodium
berghei. Sequences for the putative Toxoplasma gondii EF-G proteins
were retrieved using BLAST searches [34] of the Toxoplasma
Genome Resource (www.toxodb.org). All other sequences were
retrieved by text or BLAST searches of GenBank (www.ncbi.nlm.
nih.gov) . Alignments were performed and visualised using
ClustalX [35]. Accession numbers of EF-G sequences used are
included in Table S1. Analysis of N-terminal targeting information
was carried out using the Plasmodium targeting prediction programs
Plasmit [27] and PlasmoAP [29].
Cloning of PFL1590c and PFF115c localisation constructs
Constructs were created using the MultiSite Gateway system
TM
(Invitrogen), as previously described [31]. The complete predicted
open reading frames of PFL1590c and PFF0115c gene were
amplified from P. falciparum genomic DNA using the primers
shown in Table S3, with attB1 and attB2 sites underlined for the
sense and antisense primer, respectively. The PCR products were
recombined into the vector pDONR221 according to the
manufacturer’s instructions (Invitrogen) and fully sequenced.
These vectors were then recombined via LR reaction (Invitrogen)
to create a C-terminal GFP-tagged PFF0115c construct driven by
the PfHSP86 59 UTR (which we called ApicEFG-GFP) and a C-
terminal 3x hemagglutinin (HA)-tagged PFL1590c construct
driven by the PfHSP86 59 UTR (which we called MitoEFG-
HA). Both constructs carried a human DHFR expression cassette
conferring resistance the drug WR99210 [36].
Parasite Lines and Transfection
Parasites were grown as previously described [37]. The D10
parasite line was used for all transfections. D10 parasites
expressing apicoplast- targeted RFP and mitochondrial-targeted
YFP [31] were used for microscopic analysis of drug treatment
effects. Transfection of MitoEFG-HA and ApicEFG-GFP plas-
mids into P. falciparum was performed as previously described
[38,39]. Cultures were split 2:1 14 and 28 days post transfection,
yielding drug resistant parasites within 20–30 days.
Western Blotting
Western blots were performed as previously described [40].
Mouse anti-HA primary antibody was diluted 1/500, and anti-
mouse HRP secondary antibody was diluted 1/5000. Rabbit anti-
GFP primary antibody was diluted 1/500, and anti-rabbit HRP
secondary antibody was diluted 1/5000.
Immunofluorescence assays
Immunofluorescence assays were performed as previously
described [39]. For Mitotracker labelling of the P. falciparum
mitochondrion, cells were incubated in 20 nM MitoTracker Red
(Molecular Probes) diluted in 0/100 RPMI-HEPES medium for
15 mins at 37uC. Cells were washed in 0/100 medium, prior to
Figure 4. P. falciparum EF-G PFF0115c localises to the apicoplast. A. PFF0115c was fused to a C-terminal GFP tag to create the construct
ApicEFG-GFP. B. Western blot analysis of D10 parasites expressing ApicEFG-GFP reveals a single band at approximately the predicted molecular mass
of the PFF0115c protein attached to a GFP tag. C. An immunofluorescence assay on D10 parasites expressing ApicEFG-GFP reveals that PFF0115c is
localised to the P. falciparum apicoplast. ApicEFG-GFP (green) co-localises with ACP labelling of the apicoplast (red), and shows the dot-like organelle
typical of the P. falciparum apicoplast during the ring stage of the asexual cycle [23]. DNA stained with Hoescht 33342 (blue).
doi:10.1371/journal.pone.0020633.g004
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diluted 1/200. Anti-rat antibody conjugated to Alexafluor 488
(Molecular Probes) was diluted 1/1000. Rabbit anti-ACP antibody
[30] was diluted 1/1000, as was anti-rabbit antibody conjugated to
Alexafluor 546 (Molecular Probes).
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